Full Press Release Details
Melbourne (Australia) | 4 April 2025
Telix today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 2025 [1] .
Ms. Whitaker is a seasoned healthcare leader and advisor with over 30 years’ global corporate experience spanning large pharmaceutical, biotech and speciality pharmaceutical companies, including clinical research and manufacturing organizations. She has held Board positions on a range of Nasdaq-listed clinical and commercial stage life sciences companies. Ms. Whitaker is currently serving as a NED at Icon PLC (NASDAQ: ICLR) and is Chair at QurAlis Corporation.
Ms. Whitaker is an accomplished C-suite leader, most recently as Chair and CEO of Aerami Therapeutics Holdings Inc. During her executive career she has held senior leadership roles at GlaxoSmithKline (GSK), Sanofi and Bausch Health. Ms. Whitaker holds a Bachelor of Science in Chemistry and Business from the University of North Alabama.
Telix Chairman, H Kevin McCann AO, said, “Anne is an outstanding addition to our Board. She brings industry-relevant expertise across commercial risk management, mergers and acquisitions and Nasdaq governance, with experience across a vast range of global, growth-focused healthcare companies. The Board looks forward to Anne’s contributions as Telix continues to grow globally.”
Read the full ASX release here
[1] Ms. Whitaker will also be appointed as a member of the Audit and Risk Committee and the People Committee.